CRITICAL-EVALUATION OF THIORIDAZINE BIOEQUIVALENCE

被引：11

作者：

BARONE, JA ^{[1
]}

COLAIZZI, JL ^{[1
]}

机构：

[1] RUTGERS STATE UNIV,MIDDLESEX GEN HOSP,NEW BRUNSWICK,NJ 08903

来源：

DRUG INTELLIGENCE & CLINICAL PHARMACY | 1985年 / 19卷 / 11期

关键词：

D O I：

10.1177/106002808501901124

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：847 / 858

页数：12

共 42 条

[1] [Anonymous], 1980, Psychopharmacol Bull, V16, P9
[2] AXELSSON R, 1977, CURR THER RES CLIN E, V21, P561
[3] THERAPEUTIC IMPLICATIONS OF BIOAVAILABILITY
AZARNOFF, DL
HUFFMAN, DH
[J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1976, 16 : 53 - 66
[4] BANKIER RG, 1972, DIS NERV SYST, V33, P529
[5] BARONE J, 1984, POISINDEX
[6] GENERIC THIORIDAZINE FAILURE
BROWNING, G
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (09): : 738 - 739
[7] BYCK R, 1975, PHARMACOL BASIS, P152
[8] BYLUND DB, 1981, J PHARMACOL EXP THER, V217, P81
[9] Cabana B E, 1983, Health Aff (Millwood), V2, P33, DOI 10.1377/hlthaff.2.3.33
[10] ASSESSMENT OF 75/75 RULE - FDA VIEWPOINT
CABANA, BE
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (01) : 98 - 99